Spots Global Cancer Trial Database for BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma

Official Title: Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma

Study ID: NCT01925599

Conditions

Choroidal Nevi, Uveal Melanoma

Interventions

Study Description

Brief Summary: The BAP1 trial will examine the blood of patients diagnosed with choroidal nevi or uveal melanoma for a germline BAP1 mutation and other genetic markers associated with developing malignancy as well as additional sequencing of the uveal melanoma genome.

Detailed Description: A germline BAP1 mutation predisposes a person to developing uveal melanoma and other cancers. If a mutation is discovered, it changes the potential approach to managing the nevus. In the presence of a known genomic change associated with aggressive disease, closer follow up and more aggressive treatment could preserve the patient's vision and prevent micrometastatic spread. This new screening technique will be able to extend the length and quality of life of patients with more frequent targeted cancer screens.